Virus infection-preventing molded product and its manufacturing method

Abstract

To provide a synthetic resin-made virus infection-inhibiting molding having excellent effect of inhibiting virus infection.SOLUTION: A virus infection-inhibiting molding includes: a synthetic resin; and a particulate virus infection-inhibiting agent contained in a dispersion state in the synthetic resin, where an aggregation degree of the particulate virus infection-inhibiting agent is controlled as a standard deviation σ of a volume fraction of the virus infection-inhibiting agent in a width direction measured by X-ray CT is 0.1 to 5, and a surface of the virus infection-inhibiting molding is configured so that the virus infection-inhibiting agent easily exists thereon while making a surface area of the particulate virus infection-inhibiting agent large to have excellent virus infection-inhibiting effect.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a virus infection-preventing molded article and a method for producing the same. [Background technology]

[0002] In recent years, in addition to seasonal influenza virus epidemics, the novel coronavirus (COVID-19) has become a global pandemic.

[0003] Furthermore, highly pathogenic avian influenza viruses have mutated and been confirmed to infect humans, and there are also concerns about the SARS virus, which has an extremely high mortality rate, so anxiety about viruses is only increasing.

[0004] To address these problems, Patent Document 1 proposes an antiviral synthetic resin composition containing 0.5 parts by mass or more of a sulfonic acid surfactant per 100 parts by mass of synthetic resin. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Japanese Patent Application Laid-Open No. 2016-128395 Summary of the Invention [Problem to be solved by the invention]

[0006] However, the above-mentioned antiviral synthetic resin composition merely contains a sulfonic acid surfactant in a synthetic resin, and the synthetic resin containing a sulfonic acid surfactant does not have sufficient antiviral properties (viral infection prevention effect), and therefore a molded article made of a synthetic resin having an excellent viral infection prevention effect is desired.

[0007] The present invention provides a virus infection-preventing molded article made of synthetic resin that has an excellent virus infection-preventing effect. [Means for solving the problem]

[0008] The virus infection-inhibiting molded article of the present invention comprises a synthetic resin and a particulate virus infection inhibitor dispersed in the synthetic resin, and is characterized in that the standard deviation σ of the volume fraction of the virus infection inhibitor in the width direction as measured by X-ray CT is 0.1 to 5.

[0009] The method for producing a virus infection-inhibiting molded article of the present invention is characterized by comprising a step of melt-kneading the particulate virus infection-inhibiting agent and a synthetic resin. [Effects of the Invention]

[0010] The virus infection-blocking molded article of the present invention has a standard deviation σ of the volume fraction of the virus infection inhibitor in the width direction as measured by X-ray CT of 0.1 to 5, so that the degree of aggregation of the particulate virus infection inhibitor is controlled, the surface area of ​​the particulate virus infection inhibitor is increased, and the virus infection inhibitor is easily present on the surface of the virus infection-blocking molded article. Therefore, the virus infection-blocking molded article has an excellent virus infection-blocking effect due to the virus infection inhibitor. DETAILED DESCRIPTION OF THE INVENTION

[0011] The virus infection-inhibiting molded article contains a synthetic resin and a particulate virus infection-inhibiting agent dispersed in the synthetic resin, and the standard deviation σ of the volume fraction of the virus infection-inhibiting agent in the width direction measured by X-ray CT is 0.1 to 5.

[0012] The virus infection-blocking molded article has a particulate virus infection inhibitor dispersed in a synthetic resin. As a result of investigations by the inventors, it was found that the virus infection-blocking effect of the virus infection-blocking molded article cannot be effectively achieved by simply incorporating the virus infection inhibitor in the synthetic resin.

[0013] The inventors focused on the dispersion state of particulate virus infection inhibitors in synthetic resins and discovered that by controlling the dispersion state of the virus infection inhibitors, the virus infection inhibitors' virus infection inhibitory effect can be effectively exerted, and as a result, excellent virus infection inhibitory effects can be imparted to virus infection-inhibiting molded articles.

[0014] [Synthetic resin] The virus infection-blocking molded article contains a synthetic resin. Any known synthetic resin can be used as long as it can be used to produce a molded article. The synthetic resin is not particularly limited, and examples thereof include thermoplastic resins (e.g., polyolefin resins such as polyethylene and polypropylene, polyvinyl chloride, polystyrene, polyvinyl acetate, polystyrene, ABS resin, AS resin, polymethyl methacrylate, polyurethane, Teflon (registered trademark), acrylonitrile butadiene styrene resin, acrylonitrile styrene resin, acrylic resin, polyvinyl alcohol, polyamide, polyacetal, polycarbonate, modified polyphenylene ether, polyester, polyethylene terephthalate, polybutylene terephthalate, cyclic polyolefin, polyphenylene sulfide, polytetrafluoroethylene, polysulfone, polyethersulfone, polyarylate, polyetheretherketone, thermoplastic polyimide, polyamideimide, etc.), and thermosetting resins (e.g., phenolic resin, epoxy resin, melamine resin, urea resin, unsaturated polyester resin, alkyd resin, silicone resin, polyurethane, thermosetting polyimide, etc.). The synthetic resins may be used alone or in combination of two or more.

[0015] [Virus infection inhibitor] The virus infection-blocking molded article contains a virus infection inhibitor. The virus infection-blocking molded article exhibits a virus infection-blocking effect due to the action of the virus infection inhibitor. The virus infection inhibitor is not particularly limited as long as it exhibits a virus infection-blocking effect and is particulate. The virus infection inhibitor preferably contains at least one compound selected from the group consisting of an organic acid, an alkylbenzene sulfonate, and an amine compound as an active ingredient, more preferably at least one compound selected from the group consisting of an organic acid and an alkylbenzene sulfonate, and more preferably an organic acid. The active ingredient of the virus infection inhibitor is preferably at least one compound selected from the group consisting of an organic acid, an alkylbenzene sulfonate, and an amine compound, more preferably at least one compound selected from the group consisting of an organic acid and an alkylbenzene sulfonate, and more preferably an organic acid. Preferably, at least one compound selected from the group consisting of an organic acid, an alkylbenzene sulfonate, and an amine compound is used as the virus infection inhibitor, more preferably at least one compound selected from the group consisting of an organic acid and an alkylbenzene sulfonate, and more preferably an organic acid.

[0016] In the present invention, an organic compound refers to a compound containing at least one carbon atom (preferably two or more) and a carbon-hydrogen bond (C—H bond) in the molecule.

[0017] Here, the term "viral infection inhibitory effect" refers to the effect of eliminating or reducing the infectivity of a virus to a cell, or of preventing the virus from replicating in the cell even if it infects. Examples of methods for confirming the presence or absence of such viral infectivity include ISO 18184 and JIS L 1922 for textile products, and ISO 21702 for plastics and non-porous surface products other than textile products. Other methods include the plaque method and hemagglutination titer (HAU) assay described in "Medical and Pharmaceutical Virology" (first published April 1990).

[0018] The virus infection inhibitory effect of a virus infection inhibitor can be measured, for example, as follows. 5 parts by mass of the virus infection inhibitor and 95 parts by mass of a synthetic resin are melt-kneaded and mixed to produce a resin composition, which is then press-molded to produce a sheet-like synthetic resin molded product with an average thickness of 1 mm. The surface of the resulting synthetic resin molded product is wiped with a flat square nonwoven fabric measuring 10 cm on a side, moving the nonwoven fabric back and forth 10 times, and this synthetic resin molded product is used as a test specimen.

[0019] The obtained test specimens are subjected to antiviral tests in accordance with ISO 21702. After the reaction, the virus suspension is subjected to the plaque method to measure the virus infectivity (common logarithm) (PFU / cm) of the test coating. 2 ) is calculated.

[0020] A blank reference sample was prepared in the same manner as above, except that no virus infection inhibitor was added. Based on this blank reference sample, the virus infectivity (common logarithm) (PFU / cm) was calculated in the same manner as above. 2 ) is calculated.

[0021] The antiviral activity value is calculated by subtracting the viral infectivity of the test sample from the viral infectivity of the blank reference sample.

[0022] The antiviral activity value of the viral infection inhibitor 10 minutes after the start of the reaction in an antiviral test in accordance with ISO 21702 is preferably 2.0 or higher, more preferably 2.5 or higher, and even more preferably 2.8 or higher. Regardless of the type of virus being evaluated, it is preferable that the antiviral activity value be 2.0 or higher for at least one type of virus.

[0023] The viral infection inhibitor preferably contains an organic acid as an active ingredient. The organic acid is preferably an organic compound, and may be a polymer. The organic acid has a carboxy group (-COOH), a sulfo group (-SO3H), a phosphonic acid group [-P(=O)(OH)2], or a phosphate group [-OPO(OH)2] in the molecule, and may have only one of these functional groups or multiple types of functional groups. The organic acid preferably has a carboxy group, since this provides the viral infection inhibitor with an excellent viral infection inhibitory effect.

[0024] The content of the organic acid in the virus infection inhibitor is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.

[0025] The organic acid preferably has a plurality of functional groups selected from the group consisting of a carboxy group (-COOH), a sulfo group (-SO3H), a phosphonic acid group [-P(=O)(OH)2], and a phosphate group [-OPO(OH)2] in the molecule, more preferably a carboxy group among the plurality of functional groups, and even more preferably a plurality of carboxy groups. When the organic acid has a plurality of the above functional groups, the virus infection-inhibiting molded article exhibits an excellent virus infection-inhibiting effect. It is preferable that the organic acid does not contain a salt of a sulfo group, a salt of a phosphonic acid group [-P(=O)(OH)2], or a salt of a phosphate group [-OPO(OH)2] in the molecule.

[0026] The organic acid is not particularly limited as long as it has a carboxy group (-COOH), a sulfo group (-SO3H), a phosphonic acid group [-P(=O)(OH)2] or a phosphate group [-OPO(OH)2] in the molecule.

[0027] Examples of organic acids include adipic acid (solubility: 14 g / L), benzoic acid (solubility: 3.4 g / L), lauric acid (solubility: 0 g / L), azelaic acid (solubility: 2.4 g / L), sebacic acid (solubility: 0.25 g / L), dodecanedioic acid (solubility: 0 g / L), fumaric acid (solubility: 6.3 g / L), phthalic acid (solubility: 7.2 g / L), and isophthalic acid (solubility: 0.13 g / L). L), terephthalic acid (solubility: 0.017 g / L), methylenedisalicylic acid (solubility: 0 g / L), cis-Δ4-tetrahydrophthalic acid (solubility: 0 g / L), caproic acid (solubility: 11 g / L), enanthic acid (solubility: 2.4 g / L), caprylic acid (solubility: 0.68 g / L), pelargonic acid (solubility: 0.28 g / L), capric acid (solubility: 0.15 g / L), lauryl ether Phosphoric acid (solubility: 0.0048 g / L), myristic acid (solubility: 0 g / L), palmitic acid (solubility: 0 g / L), stearic acid (solubility: 0 g / L), myristoleic acid (solubility: 0 g / L), oleic acid (solubility: 0 g / L), ricinoleic acid (solubility: 0 g / L), salicylic acid (solubility: 2.0 g / L), gallic acid hydrate (solubility: 11 g / L), benzilic acid (solubility: 1 Examples of organic acids include benzoic acid (solubility: 0.4 g / L), 4-aminobenzoic acid (solubility: 6 g / L), triglycolaminic acid (solubility: 1.3 g / L), polyacrylic acid (solubility: 250 g / L or more), 1,3-propanediaminetetraacetic acid (solubility: 9 g / L), diethylenetriaminepentaacetic acid (solubility: 4 g / L), and alginic acid (solubility: 0 g / L), with isophthalic acid, terephthalic acid, and alginic acid being preferred. The solubilities listed in parentheses are the solubility of the organic acid in water at 25°C. The organic acids may be used alone or in combination of two or more.

[0028] When the organic acid is a polymer, examples of the organic acid include a linear polymer having a carboxyl group (-COOH), a sulfo group (-SOH), a phosphonic acid group [-P(=O)(OH)], or a phosphate group [-OPO(OH)] on the side chain.

[0029] In the case of a polymer having a carboxy group (-COOH), a sulfo group (-SOH), a phosphonic acid group [-P(=O)(OH)] or a phosphoric acid group [-OPO(OH)] in the side chain of the linear polymer, the linear polymer is not particularly limited, and for example, a vinyl polymer, a polyester or a polyurethane is preferred, with a vinyl polymer being preferred.

[0030] The polymer having a carboxy group (-COOH), a sulfo group (-SOH), a phosphonic acid group [-P(=O)(OH)] or a phosphate group [-OPO(OH)] in the side chain of the linear polymer is not particularly limited, and examples thereof include a polymer containing a monomer component having a carboxy group, a polymer containing a monomer component having a sulfo group, a polymer containing a monomer component having a phosphonic acid group [-P(=O)(OH)], and a polymer containing a monomer component having a phosphate group [-OPO(OH)].

[0031] Examples of the monomer having a carboxy group include acrylic acid, methacrylic acid, acrylic acid, methacrylic acid, β-carboxyethyl (meth)acrylate, 5-carboxypentyl (meth)acrylate, succinic acid mono(meth)acryloyloxyethyl ester, ω-carboxypolycaprolactone mono(meth)acrylate, crotonic acid, maleic acid, fumaric acid, itaconic acid, citraconic acid, and carboxybetaine type monomers, with acrylic acid and methacrylic acid being preferred. The monomer having a carboxy group may be used alone or in combination of two or more.

[0032] Examples of the monomer having a sulfo group include p-styrenesulfonic acid, m-styrenesulfonic acid, o-styrenesulfonic acid, acrylamido-t-butylsulfonic acid, vinylsulfonic acid, 2-(methacryloyloxy)ethanesulfonic acid, 3-(methacryloyloxy)propanesulfonic acid, 4-[(3-methacrylamidopropyl)dimethylammonio]butane-1-sulfonic acid, etc. The monomer having a sulfo group may be used alone or in combination of two or more kinds.

[0033] Examples of the monomer having a phosphonic acid group include vinylphosphonic acid, alkyl vinylphosphonate, etc. The monomer having a phosphonic acid group may be used alone or in combination of two or more kinds.

[0034] Examples of the monomer having a phosphoric acid group include monoacrylate phosphoric acid, diacrylate phosphoric acid, monomethacrylate phosphoric acid, dimethacrylate phosphoric acid, 2-hydroxyethyl methacrylic acid phosphoric acid, etc. The monomer having a phosphoric acid group may be used alone or in combination of two or more kinds.

[0035] When the organic acid is a polymer, the total content of monomer components having a carboxy group (-COOH), a sulfo group (-SOH), a phosphonic acid group [-P(=O)(OH)] or a phosphate group [-OPO(OH)] in the polymer is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.

[0036] A polymer having a carboxy group (-COOH), a sulfo group (-SOH), a phosphonic acid group [-P(=O)(OH)] or a phosphate group [-OPO(OH)] in the side chain of a linear polymer may contain a monomer component copolymerizable with a monomer having a carboxy group (-COOH), a sulfo group (-SOH), a phosphonic acid group [-P(=O)(OH)] or a phosphate group [-OPO(OH)].

[0037] Examples of the copolymerizable monomer include alkyl acrylate, alkyl methacrylate, vinyl alkyl ether, vinyl acetate, ethylene, propylene, butylene, butadiene, diisobutylene, vinyl chloride, vinylidene chloride, 2-vinylnaphthalene, styrene, acrylonitrile, sodium acrylate, acrylamide, methacrylamide, diacetone acrylamide, vinyl toluene, vinyl pyridine, methyl methacrylate, sodium methacrylate, and hydroxyethyl methacrylate.

[0038] Linear polymers having a carboxyl group (-COOH), a sulfo group (-SO3H), a phosphonic acid group [-P(=O)(OH)2], or a phosphoric acid group [-OPO(OH)2] in the side chain can be produced by a general-purpose radical polymerization method.

[0039] The solubility of the organic acid in water at 25°C (solubility in water at 25°C) is preferably 20 g / L or less, and more preferably 18 g / L or less. When the solubility of the organic acid in water at 25°C is 20 g / L or less, the interaction between the organic acid and viruses is improved, and the virus infection-inhibiting molded article can be imparted with an excellent virus infection-inhibiting effect. The solubility of the organic acid in water at 25°C refers to the mass of the organic acid that dissolves in 1 L of water.

[0040] The solubility of the organic acid in water at 25° C. is preferably 0.001 g / L or more, more preferably 0.01 g / L or more, and even more preferably 0.015 g / L or more. When the organic acid has a solubility in water at 25° C. of 0.001 g / L or more, upon contact with an aqueous protein solution containing viruses, such as saliva or sputum, the interaction between the organic acid and viruses is improved, and an excellent viral infection-inhibiting effect can be imparted to the viral infection-inhibiting molded article.

[0041] The solubility of organic acids in water at 25°C is the value measured at 25°C in accordance with OECD Chemicals Testing Guideline No. 105 (Water Solubility).

[0042] The virus infection inhibitor preferably contains an alkylbenzenesulfonate as an active ingredient, such as sodium dodecylbenzenesulfonate, potassium dodecylbenzenesulfonate, ammonium dodecylbenzenesulfonate, and triethanolammonium dodecylbenzenesulfonate.

[0043] The content of alkylbenzene sulfonate in the virus infection inhibitor is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.

[0044] The number of carbon atoms in the alkyl group of the alkylbenzene sulfonate is preferably 8 or more, and more preferably 10 or more. The number of carbon atoms in the alkyl group of the alkylbenzene sulfonate is preferably 25 or less, more preferably 20 or less, and more preferably 18 or less. When the alkyl group has 8 or more carbon atoms, the dispersibility of the alkylbenzene sulfonate in the resin is increased, and the interaction between the alkylbenzene sulfonate and viruses is improved, thereby improving the viral infection-inhibiting effect of the viral infection-inhibiting molded product. When the alkyl group has 25 or less carbon atoms, the interaction between the alkylbenzene sulfonate and viruses is improved, and the viral infection-inhibiting effect of the viral infection-inhibiting molded product is improved.

[0045] The virus infection inhibitor preferably contains an amine compound as an active ingredient, such as a compound having at least one amino functional group selected from the group consisting of a primary amino group, a secondary amino group, and a tertiary amino group, or a salt thereof in the molecule.

[0046] The content of the amine compound in the virus infection inhibitor is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.

[0047] The amino functional group preferably contains a secondary amino group because this improves the viral infection-blocking effect of the viral infection-blocking molded article, and the amino functional group preferably contains a secondary amino group because it has a viral infection-blocking effect against both enveloped and non-enveloped viruses.

[0048] The amino functional group preferably forms a cyclic skeleton, and more preferably an alicyclic cyclic skeleton, because this improves the viral infection inhibitory effect of the viral infection inhibitor and can generally prevent whitening of the substrate surface even when the viral infection inhibitor is contained in a substrate.

[0049] A primary amino group refers to a monovalent substituent represented by -NH2. A secondary amino group refers to a divalent substituent (-NH-) resulting from removing (pulling out) one hydrogen atom from -NH2. A tertiary amino group refers to a trivalent substituent [≡N, formula (a)] resulting from removing (pulling out) two hydrogen atoms from -NH2. However, the amino functional group does not include a case where a keto group (>CO) is directly bonded to the nitrogen atom constituting the amino functional group.

[0050] [ka]

[0051] The salt of the amino functional group is not particularly limited, but an acid addition salt is preferred. Examples of the acid for the acid addition salt include hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, phosphorous acid, hydrobromic acid, maleic acid, malic acid, ascorbic acid, tartaric acid, lauric acid, stearic acid, palmitic acid, oleic acid, myristic acid, lauryl sulfuric acid, linolenic acid, and fumaric acid, and hydrochloride is preferred.

[0052] The amine compound is preferably a polymeric compound having an amino functional group or a salt thereof, such as a polymer having an amino functional group or a salt thereof in the side chain of a linear polymer.

[0053] In the polymer containing an amino functional group or a salt thereof in the side chain of a linear polymer, the linear polymer is not particularly limited, and for example, vinyl polymers and polyesters are preferred, with vinyl polymers being more preferred.

[0054] Examples of polymers containing an amino functional group or a salt thereof in the side chain of a linear polymer include polymers containing, as monomer units, an amino functional group-containing monomer containing an amino functional group or a salt thereof.

[0055] The amino functional group-containing monomer containing an amino functional group or a salt thereof is not particularly limited, and examples thereof include 2-vinylpyridine, 4-vinylpyridine, vinylimidazole, dimethylaminoethyl (meth)acrylate, diethylaminoethyl (meth)acrylate, t-butylaminoethyl (meth)acrylate, N-(aminoalkyl)acrylamide, N-(aminoalkyl)methacrylamide, a monomer obtained by reacting glycidyl (meth)acrylate with ammonia or dimethylamine, allylamine, diallylamine, methyldiallylamine, 1,2,2,6,6-pentamethyl-4-piperidyl methacrylate, 2,2,6,6-tetramethyl-4-piperidyl methacrylate, or salts of these amino functional groups. The amino functional group-containing monomer containing an amino functional group or a salt thereof may be used alone or in combination of two or more.

[0056] The polymer containing the amino functional group-containing monomer as a monomer unit may be a homopolymer of the amino functional group-containing monomer, or a copolymer of the amino functional group-containing monomer and a monomer copolymerizable therewith.

[0057] The monomer copolymerizable with the amino functional group-containing monomer is not particularly limited, and examples thereof include alkyl acrylate, alkyl methacrylate, vinyl alkyl ether, vinyl acetate, ethylene, propylene, butylene, butadiene, diisobutylene, vinyl chloride, vinylidene chloride, 2-vinylnaphthalene, styrene, acrylonitrile, acrylamide, methacrylamide, diacetone acrylamide, vinyl toluene, etc. The monomer copolymerizable with the amino functional group-containing monomer may be used alone or in combination of two or more.

[0058] The content of the active ingredient in the viral infection inhibitor is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.

[0059] The virus infection inhibitor may be supported by a filler, or may not be supported by a filler. The virus infection inhibitor may be in a particulate form by supporting the active ingredient (and any added ingredients) on the surface of a filler. The virus infection inhibitor may not be supported by a filler, but may be processed into particles by pulverizing, granulating, or the like.

[0060] The filler is not particularly limited as long as it does not inhibit the viral infection inhibitory effect of the viral infection inhibitor. Examples of the filler include resin particles and inorganic particles. The filler may be used alone or in combination of two or more types.

[0061] Examples of synthetic resins that make up the resin particles include styrene-based resins, acrylic-based resins, urethane-based resins, vinyl chloride-based resins, ABS resins; and synthetic rubbers such as styrene-butadiene rubber (SBR) and nitrile-butadiene rubber (NBR).

[0062] The inorganic material constituting the inorganic particles is not particularly limited, and examples thereof include zeolite, hydrotalcite, calcium carbonate, calcium citrate, magnesium carbonate, and magnesium hydroxide.

[0063] The content of the virus infection inhibitor in the virus infection-blocking molded product is preferably 1 part by mass or more, and more preferably 2 parts by mass or more, per 100 parts by mass of synthetic resin. There is no particular upper limit to the content of the virus infection inhibitor in the virus infection-blocking molded product, but it is preferably 80 parts by mass or less, more preferably 75 parts by mass or less, and more preferably 70 parts by mass or less, per 100 parts by mass of synthetic resin. When the content of the virus infection inhibitor is 1 part by mass or more, the virus infection-blocking molded product can be imparted with an excellent virus infection-blocking effect. When the content of the virus infection inhibitor is 80 parts by mass or less, it is easier to ensure performance such as strength of the virus infection-blocking molded product.

[0064] In the virus infection-blocking molded product, the content of the active ingredient is preferably 1 part by mass or more, and more preferably 2 parts by mass or more, per 100 parts by mass of synthetic resin. There is no particular upper limit to the content of the active ingredient in the virus infection-blocking molded product, but it is preferably 80 parts by mass or less, more preferably 75 parts by mass or less, and even more preferably 70 parts by mass or less, per 100 parts by mass of synthetic resin. When the content of the active ingredient is 1 part by mass or more, the virus infection-blocking molded product can be imparted with an excellent virus infection-blocking effect. When the content of the active ingredient is 80 parts by mass or less, it is easier to ensure the strength and other performance properties of the virus infection-blocking molded product.

[0065] The inventors noticed that even when the same amount of virus infection inhibitor is contained in the synthetic resin that makes up the virus infection-blocking molded body, there are differences in the virus infection-blocking effect due to the action of the virus infection inhibitor.As a result of extensive research, the inventors discovered that the difference in the degree of aggregation of the virus infection inhibitor dispersed in the synthetic resin affects the virus infection-blocking effect of the virus infection-blocking molded body.

[0066] In detail, it was found that the particulate virus infection inhibitor in the virus infection-blocking molded product varies in its likelihood of being present on the surface of the virus infection-blocking molded product depending on the degree of aggregation of the particles; the greater the degree of aggregation of the particulate virus infection inhibitor, the more likely it is to be present on the surface of the virus infection-blocking molded product, improving the virus infection-blocking effect of the virus infection-blocking molded product; on the other hand, the greater the degree of aggregation of the particulate virus infection inhibitor, the smaller the surface area of ​​the virus infection inhibitor and the smaller the interaction between the virus and the virus.The present invention improves the virus infection-blocking effect of the virus infection-blocking molded product by adjusting the degree of aggregation of the virus infection inhibitor in the synthetic resin to control the dispersion state.

[0067] For the virus infection inhibitor, the standard deviation σ of the volume fraction of the virus infection inhibitor in the width direction (hereinafter sometimes simply referred to as "volume fraction") measured by X-ray CT is 0.1 or more, preferably 0.11 or more, and more preferably 0.12 or more. For the virus infection inhibitor, the standard deviation σ of the volume fraction of the virus infection inhibitor in the width direction measured by X-ray CT is 5 or less, preferably 4 or less, and more preferably 3 or less. By adjusting the standard deviation σ of the volume fraction of the virus infection inhibitor within the above range, the virus infection inhibitor is moderately aggregated to prevent a decrease in surface area due to excessive aggregation of the virus infection inhibitor, while exposing more of the virus infection inhibitor to the surface of the virus infection-blocking molded article, thereby improving the virus infection-blocking effect of the virus infection-blocking molded article.

[0068] For the virus infection-blocking molded article, the equivalent sphere diameter measured by X-ray CT (hereinafter sometimes simply referred to as "equivalent sphere diameter") is preferably 5 μm or more, more preferably 5.5 μm or more, and more preferably 6 μm or more. For the virus infection-blocking agent, the equivalent sphere diameter measured by X-ray CT is preferably 30 μm or less, more preferably 25 μm or less, and more preferably 20 μm or less. When the equivalent sphere diameter of the virus infection-blocking agent is within the above range, the virus infection-blocking agent can be appropriately aggregated to expose more of it on the surface of the virus infection-blocking molded article, while preventing a decrease in surface area due to excessive aggregation of the virus infection-blocking agent, thereby improving the virus infection-blocking effect of the virus infection-blocking molded article.

[0069] For the virus infection inhibitor, the standard deviation σ of the volume fraction of the virus infection inhibitor in the width direction measured by X-ray CT and the sphere-equivalent diameter measured by X-ray CT are values ​​measured as follows.

[0070] For example, the measurement can be performed using the following measurement device and under the following measurement conditions. (X-ray CT using equipment) 3D X-ray microscope ("High-resolution 3D X-ray microscope nano3DX" manufactured by Rigaku Corporation) (X-ray CT measurement conditions) X-ray target: Cu Lens: L01080 (1.08 μm / pixel) Binning: 2 Exposure time: 6 seconds Number of shots: 1000 Sample set: Set so that the thickness direction is the Z axis (Image analysis) (i) Image stitching: For samples spanning multiple fields of view, the images are stitched together. (ii) Horizontal correction: Use the Transform Editor to adjust the surface of the virus infection-blocking molded object so that it is horizontal in the image, and then apply the Resample Transformed Image. In the Resample Transformed Image, change the Mode to extended, and leave the other conditions at their default values. (iii) Extraction of virus infection-blocking molded body region: Interactive thresholding is applied to the image in (ii) and the threshold is adjusted so that only the virus infection-blocking molded body region is extracted. (iv) Extraction of virus infection inhibitor: Interactive thresholding is applied to the image in (iii) and the threshold is adjusted so that only the virus infection inhibitor region is extracted. (v) Region division process: Separate Objects is applied to the image in (iv) to divide adjacent virus infection inhibitor regions into individual regions. The conditions for Separate Objects are as follows. Note that the conditions for Separate Objects can be changed as appropriate depending on the shooting conditions and the type of molded product. Marker Extent: 3 Other conditions are set to the default values. (vi) Image edge processing: Border Kill is applied to the image in (iv) to remove the virus infection inhibitor extraction area that is adjacent to the image edge. Note that the Border Kill conditions are set to the default values. (vii) Calculation of the volume ratio in the width direction: Material Statistics is applied to the images of (iii) and (iv) to measure the volume of each region in each cross section in the width direction. The conditions for Material Statistics are as follows: Select:Volume per slice From the measured volume, the volume fraction of the virus infection inhibitor in each cross section in the width direction is calculated using the following formula. Volume ratio of virus infection inhibitor (%) =Volume of virus infection inhibitor / Volume of virus infection inhibitor molded product × 100 Furthermore, the standard deviation is calculated from the volume fraction of the virus infection inhibitor in each cross section in the width direction. (viii) Calculation of sphere-equivalent diameter: Label analysis is applied to the image in (v), and the volume (voxel) of each virus infection inhibitor extraction area is analyzed. From the obtained volumes, the actual volume is calculated using the following formula. Actual volume (μm 3) = volume (voxel) × (resolution) 3 (μm / pixel) Furthermore, the sphere-equivalent diameter is calculated from the actual volume using the following formula. Sphere equivalent diameter (μm) = 2 × [(3 × actual volume) / (4π)]^(1 / 3)

[0071] The standard deviation σ of the volume fraction of the virus infection inhibitor can be controlled, for example, in the following ways: (1) By increasing the degree of kneading of the synthetic resin and the virus infection inhibitor, the standard deviation σ of the volume fraction of the virus infection inhibitor can be reduced; (2) By using a larger amount of a dispersant, described below, when mixing the synthetic resin and the virus infection inhibitor, the standard deviation σ of the volume fraction of the virus infection inhibitor can be reduced.

[0072] The equivalent sphere diameter of the virus infection inhibitor can be controlled, for example, in the following manner. For example, (1) the equivalent sphere diameter of the virus infection inhibitor can be reduced by increasing the degree of kneading of the synthetic resin and the virus infection inhibitor. (2) The equivalent sphere diameter of the virus infection inhibitor can be reduced by using a larger amount of dispersant when mixing the synthetic resin and the virus infection inhibitor. (3) The equivalent sphere diameter of the virus infection inhibitor can be reduced by reducing the particle diameter of the particulate virus infection inhibitor before mixing with the synthetic resin.

[0073] [Dispersant] The virus infection-blocking molded article preferably contains a dispersant, which allows the particulate virus infection-blocking agent to be appropriately aggregated to form aggregated particles of an optimal size, making them more likely to be present on the surface of the virus infection-blocking molded article, and by increasing the surface area of ​​the virus infection-blocking agent, the virus infection-blocking effect of the virus infection-blocking molded article can be improved.

[0074] The dispersant is not particularly limited, and examples thereof include anionic surfactants (excluding alkylbenzenesulfonates) (hereinafter, sometimes simply referred to as "anionic surfactants"), cationic surfactants, nonionic surfactants, amphoteric surfactants, polyalkylene glycols (e.g., polyethylene glycol, polypropylene glycol, etc.), and polymers having a salt of a sulfo group in the side chain of a linear polymer, with anionic surfactants (excluding alkylbenzenesulfonates), nonionic surfactants, polyalkylene glycols, and polymers having a salt of a sulfo group in the side chain of a linear polymer being preferred.

[0075] The dispersant preferably contains an anionic surfactant (excluding alkylbenzene sulfonate) and a nonionic surfactant, and more preferably contains a compound containing a salt of a sulfo group in the molecule (excluding alkylbenzene sulfonate) and a nonionic surfactant. The dispersant preferably contains an anionic surfactant (excluding alkylbenzene sulfonate) and a compound containing a polyoxyalkylene structure in the molecule. The dispersant more preferably contains a compound containing a salt of a sulfo group in the molecule (excluding alkylbenzene sulfonate) and a compound containing a polyoxyalkylene structure in the molecule. By using the above two types of dispersants in combination, the virus infection inhibitor can be made into agglomerated particles of a more appropriate size, and the virus infection-inhibiting molded article can have a better virus infection-inhibiting effect.

[0076] The anionic surfactant is not particularly limited, and examples thereof include alkyl phosphates such as sodium dodecyl phosphate, potassium dodecyl phosphate, sodium stearyl phosphate, and potassium stearyl phosphate; polyoxyethylene alkyl ether phosphate salts such as polyoxyethylene (3) lauryl ether sodium phosphate and polyoxyethylene (3) lauryl ether potassium phosphate; polyoxyethylene alkyl phenyl ether phosphates such as polyoxyethylene (3) lauryl phenyl ether sodium phosphate and polyoxyethylene (3) lauryl phenyl ether potassium phosphate; polystyrene sulfonates, α-olefin sulfonates, alkyl diphenyl ether sulfonates, and polyoxyalkylene alkyl ether sulfate salts; and compounds containing a salt of a sulfo group (—SO3H) in the molecule, such as polystyrene sulfonates, are preferred.

[0077] It is preferable that the dispersant is a compound containing a salt of a sulfo group (-SO3H) in the molecule, because the interaction between the viral infection inhibitor and the dispersant improves the interaction of the viral infection inhibitor with viruses, thereby improving the viral infection-inhibiting effect of the viral infection-inhibiting molded article.

[0078] The nonionic surfactant is not particularly limited, and examples thereof include polyoxyalkylene alkyl ethers (e.g., polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, polyoxyethylene oleyl cetyl ether, polyoxyethylene stearyl ether, polyoxyethylene oleyl ether, polyoxyethylene polyoxypropylene lauryl ether, polyoxypropylene alkyl ethers such as polyoxypropylene cetyl ether, polyoxypropylene isocetyl ether, polyoxypropylene stearyl ether, polyoxypropylene oleyl ether, etc.), polyoxyethylene alkyl phenyl ethers, polyoxyalkylene fatty acid esters (e.g., polyoxyethylene fatty acid esters such as polyethylene glycol monostearate and polyethylene glycol distearate, polyoxypropylene fatty acid esters such as polypropylene glycol monostearate and polypropylene glycol distearate), and polyoxyethylene distyrenated phenyl ether. , sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene sorbitol fatty acid esters, glycerin fatty acid esters, polyoxyethylene glycerin fatty acid esters, polyglycerin fatty acid esters, sucrose fatty acid esters, polyoxyethylene alkylamines, polyoxyethylene fatty acid amides, fatty acid alkanolamides (for example, coconut fatty acid alkanolamides such as lauric acid diethanolamide, coconut fatty acid dimethanolamide, coconut fatty acid diethanolamide, and coconut fatty acid dipropanolamide), fatty acid alkylolamides, alkyl alkanolamides, acetylene glycol, oxyethylene adducts of acetylene glycol, polyethylene glycol polypropylene glycol block copolymers, and the like are included, with polyoxyalkylene alkyl ethers, polyoxyalkylene fatty acid esters, and fatty acid alkanolamides being preferred, and polyoxyethylene alkyl ethers, polyoxyethylene fatty acid esters, and fatty acid ethanolamides (saturated fatty acid ethanolamides are preferred) being more preferred.

[0079] The amphoteric surfactant is not particularly limited, and examples thereof include alkylaminoacetic acid betaine, alkylamidopropyl betaine, sulfobetaine, alkylamino(mono- or di-)propionate, imidazolinium betaine, alkylamine oxide, alkylaminoethylglycine, alkyldi(aminoethyl)glycine, glycine n-(3-aminopropyl) C10-16 derivative, alkylpolyaminoethylglycine, alkyl-β-alanine, alkyldiethanolamine, polyoxyalkylene alkylamine, and oxyethylene adduct surfactant of diamine.

[0080] In the polymer having a salt of a sulfo group in the side chain of a linear polymer, the linear polymer is not particularly limited, and for example, vinyl polymers, polyesters, and polyurethanes are preferred, with vinyl polymers being preferred.

[0081] The polymer having a salt of a sulfo group in the side chain of a linear polymer is not particularly limited, and examples thereof include a polymer containing a styrene sulfonate component, a styrene sulfonate homopolymer, a styrene-styrene sulfonate copolymer, a sulfonate of a compound obtained by sulfonating the benzene ring of polystyrene, and a sulfonate of a compound obtained by sulfonating the benzene ring of a polymer containing a styrene component.

[0082] Furthermore, the polymer having a sulfo group salt in the side chain of the linear polymer is preferably a homopolymer or copolymer of a monomer having a sulfo group salt. Examples of the monomer having a sulfo group salt include sodium p-styrenesulfonate, sodium m-styrenesulfonate, sodium o-styrenesulfonate, calcium p-styrenesulfonate, calcium m-styrenesulfonate, calcium o-styrenesulfonate, ammonium p-styrenesulfonate, ammonium m-styrenesulfonate, ammonium o-styrenesulfonate, sodium naphthalenesulfonate, and calcium naphthalenesulfonate. Sodium styrenesulfonate is preferred, and sodium p-styrenesulfonate is more preferred because it has less steric hindrance in reactivity with viruses.

[0083] The monomer having a salt of a sulfo group may form a copolymer with another monomer. Examples of copolymerizable monomers include alkyl acrylate, alkyl methacrylate, vinyl alkyl ether, vinyl acetate, ethylene, propylene, butylene, butadiene, diisobutylene, vinyl chloride, vinylidene chloride, 2-vinylnaphthalene, styrene, acrylonitrile, acrylic acid, sodium acrylate, methacrylic acid, maleic acid, fumaric acid, maleic anhydride, acrylamide, methacrylamide, diacetone acrylamide, vinyl toluene, xylene sulfonic acid, vinyl pyridine, vinyl sulfonic acid, vinyl alcohol, methyl methacrylate, sodium methacrylate, and hydroxyethyl methacrylate, with styrene being preferred.

[0084] A polymer having a salt of a sulfo group in the side chain of a linear polymer can be produced by a general method, such as a method of radically polymerizing a monomer having a salt of a sulfo group, a method of radically polymerizing a monomer having a salt of a sulfo group and a monomer copolymerizable with this monomer, or a method of neutralizing the sulfo group of a polymer containing a monomer component having a sulfo group with an alkali (e.g., sodium hydroxide, calcium hydroxide, potassium hydroxide, ammonium hydroxide, etc.).

[0085] The weight-average molecular weight of the linear polymer having a sulfo salt in its side chain is preferably at least 3000, preferably at least 5000, more preferably at least 10000, and even more preferably at least 100000. When the weight-average molecular weight of the linear polymer having a sulfo salt in its side chain is 3000 or more, the compatibility of the linear polymer having a sulfo salt in its side chain with the synthetic resin is improved, and the dispersibility of the viral infection inhibitor in the synthetic resin can be improved.

[0086] The weight-average molecular weight of the linear polymer having a sulfo salt in its side chain is preferably not more than 1,000,000, more preferably not more than 900,000, more preferably not more than 800,000, and even more preferably not more than 500,000. When the weight-average molecular weight of the linear polymer having a sulfo salt in its side chain is 1,000,000 or less, the linear polymer having a sulfo salt in its side chain can be brought closer to the viral infection inhibitor, improving the dispersibility of the viral infection inhibitor in the synthetic resin.

[0087] In the present invention, the weight average molecular weight of the linear polymer having a salt of a sulfo group in the side chain is a value measured by GPC (gel permeation chromatography) and converted into polystyrene.

[0088] For example, the measurement can be performed using the following measurement device and under the following measurement conditions. Gel permeation chromatograph: Waters, product name "2690 Separations Model" Column: Showa Denko Co., Ltd., product name "GPC KF-806L" Detector: differential refractometer Sample flow rate: 1 mL / min Column temperature: 40℃ Eluent: THF

[0089] The dispersant preferably contains a polyoxyalkylene structure in its molecule, more preferably a polyoxyethylene structure. A dispersant containing a polyoxyalkylene structure in its molecule acts to cause the virus infection inhibitor, particularly the organic acid, to segregate (bleed out) onto the surface of the virus infection-blocking molded article, resulting in the virus infection-blocking molded article exhibiting excellent virus infection-blocking effects.

[0090] The polyoxyalkylene structure means a repeating unit represented by the following general formula: -(R 1 -O)n- (In the formula, R 1represents an alkylene group having 1 to 3 carbon atoms, and n is the number of repeating units and is a natural number of 2 or more.

[0091] An alkylene group is a divalent atomic group formed by removing two hydrogen atoms bonded to two different carbon atoms in an aliphatic saturated hydrocarbon, and includes both linear and branched atomic groups. Note that branched includes cases where one carbon (methyl group) is bonded as a side chain.

[0092] Examples of the alkylene group include an ethylene group, a propylene group [-CH(CH3)-CH2-], a trimethylene group [-CH2-CH2-CH2-], a butylene group, an amylene group [-(CH2)5-], and a hexylene group, with an ethylene group and a propylene group being preferred, and an ethylene group being more preferred.

[0093] The content of the dispersant in the virus infection-blocking molded product is preferably 0.1 parts by mass or more, more preferably 0.15 parts by mass or more, and more preferably 0.2 parts by mass or more, per 100 parts by mass of synthetic resin. The content of the dispersant in the virus infection-blocking molded product is preferably 30 parts by mass or less, more preferably 20 parts by mass or less, and more preferably 10 parts by mass or less, per 100 parts by mass of synthetic resin. When the content of the dispersant is 0.1 parts by mass or more, an excellent virus infection-blocking effect can be imparted to the virus infection-blocking molded product. When the content of the dispersant is 30 parts by mass or less, the virus infection-blocking agent is not coated with the dispersant, improving its interaction with the virus and improving the virus infection-blocking effect.

[0094] In the virus infection-blocking molded product, the ratio of the virus infection inhibitor content to the dispersant content (mass of virus infection inhibitor / mass of dispersant) is preferably 0.5 or more, more preferably 0.6 or more, and even more preferably 0.7 or more. In the virus infection-blocking molded product, the ratio of the virus infection inhibitor content to the dispersant content (mass of virus infection inhibitor / mass of dispersant) is preferably 20 or less, more preferably 18 or less, and even more preferably 16 or less. When the ratio of the virus infection inhibitor content to the dispersant content (mass of virus infection inhibitor / mass of dispersant) is 0.5 or more, the virus infection-blocking effect can be easily obtained while ensuring performance such as strength of the virus infection-blocking molded product. When the ratio of the virus infection inhibitor content to the dispersant content (mass of virus infection inhibitor / mass of dispersant) is 20 or less, the dispersibility of the virus infection inhibitor in the synthetic resin is improved, the interaction between the virus infection inhibitor and the virus is improved, and the virus infection-blocking effect of the virus infection-blocking molded product is improved.

[0095] In the virus infection-blocking molded article, the ratio of the alkylbenzene sulfonate content to the dispersant content (mass of alkylbenzene sulfonate / mass of dispersant) is preferably 0.5 or more, more preferably 0.6 or more, and even more preferably 0.7 or more. In the virus infection-blocking molded article, the ratio of the alkylbenzene sulfonate content to the dispersant content (mass of alkylbenzene sulfonate / mass of dispersant) is preferably 20 or less, more preferably 18 or less, and even more preferably 16 or less. When the ratio of the alkylbenzene sulfonate content to the dispersant content (mass of alkylbenzene sulfonate / mass of dispersant) is 0.5 or more, the virus infection-blocking effect can be easily obtained while ensuring performance such as strength of the virus infection-blocking molded article. When the ratio of the alkylbenzene sulfonate content to the dispersant content (mass of alkylbenzene sulfonate / mass of dispersant) is 20 or less, the dispersibility of the virus infection inhibitor in the synthetic resin is improved, the interaction between the virus infection inhibitor and viruses is improved, and the virus infection-blocking effect of the virus infection-blocking molded article is improved.

[0096] In the virus infection-blocking molded product, the ratio of the amine compound content to the dispersant content (mass of amine compound / mass of dispersant) is preferably 0.5 or more, more preferably 0.6 or more, and even more preferably 0.7 or more. In the virus infection-blocking molded product, the ratio of the amine compound content to the dispersant content (mass of amine compound / mass of dispersant) is preferably 20 or less, more preferably 18 or less, and even more preferably 16 or less. When the ratio of the amine compound content to the dispersant content (mass of amine compound / mass of dispersant) is 0.5 or more, the virus infection-blocking effect can be more easily obtained while ensuring performance such as strength of the virus infection-blocking molded product. When the ratio of the amine compound content to the dispersant content (mass of amine compound / mass of dispersant) is 20 or less, the dispersibility of the virus infection-blocking agent in the synthetic resin is improved, the interaction between the virus infection-blocking agent and viruses is improved, and the virus infection-blocking effect of the virus infection-blocking molded product is improved.

[0097] [Virus infection prevention molded product] The virus infection-inhibiting molded article can be produced by adding a dispersant to a particulate virus infection inhibitor and a synthetic resin, if necessary, and then melting and mixing them in a general manner. For example, a resin composition obtained by adding a dispersant to a particulate virus infection inhibitor and a synthetic resin, if necessary, can be molded by a general synthetic resin molding method to produce a virus infection-inhibiting molded article having a desired shape. Examples of general synthetic resin molding methods include extrusion molding, injection molding, and blow molding.

[0098] In the virus infection-blocking molded product, the particulate virus infection-blocking agent is dispersed in the synthetic resin while agglomerating to a moderate size to form agglomerated particles, and the virus infection-blocking agent is configured to segregate on the surface of the virus infection-blocking molded product while increasing the surface area of ​​the virus infection-blocking agent. As a result, the virus infection-blocking agent in the virus infection-blocking molded product interacts effectively with viruses, and the virus infection-blocking molded product exhibits excellent virus infection-blocking effects.

[0099] A synthetic resin molding masterbatch may be produced by mixing a synthetic resin containing a virus infection inhibitor and, if necessary, a dispersant, and this synthetic resin molding masterbatch may be used to produce a virus infection-inhibiting molded article having a desired shape using the general-purpose synthetic resin molding method described above. The synthetic resin used in the synthetic resin molding masterbatch may be any of the synthetic resins exemplified above. Only one type of synthetic resin may be used, or two or more types may be used in combination.

[0100] The synthetic resin molding masterbatch is preferably in the form of resin pellets because of its excellent moldability. By melting and molding the resin pellets, a synthetic resin molded product with excellent viral infection prevention effects can be obtained.

[0101] The shape of the resin pellets is not particularly limited, and examples include spherical, cylindrical, and prismatic shapes. From the viewpoint of pellet shape stability, a cylindrical shape is preferred. The maximum length dimension of the resin pellets is preferably 1 mm or more, more preferably 3 mm or more. The maximum length dimension of the resin pellets is preferably 10 mm or less, more preferably 7 mm or less.

[0102] The synthetic resin molding masterbatch can be used by mixing with other resin materials. The other resin materials may be resin pellets. The synthetic resin molding masterbatch and the other resin materials are mixed to obtain a mixed resin material, and then the mixed resin material is molded to obtain a virus infection-preventing molded article having excellent virus infection-preventing effect.

[0103] The content of the virus infection inhibitor in the masterbatch for synthetic resin molding is preferably 10 parts by mass or more, more preferably 15 parts by mass or more, and more preferably 20 parts by mass or more, per 100 parts by mass of the synthetic resin. The content of the virus infection inhibitor in the masterbatch for synthetic resin molding is preferably 80 parts by mass or less, more preferably 70 parts by mass or less, and more preferably 60 parts by mass or less, per 100 parts by mass of the synthetic resin.

[0104] The content of the dispersant in the synthetic resin molding masterbatch is preferably 3 parts by mass or more, more preferably 5 parts by mass or more, more preferably 8 parts by mass or more, and more preferably 10 parts by mass or more, per 100 parts by mass of the synthetic resin. The content of the dispersant in the synthetic resin molding masterbatch is preferably 40 parts by mass or less, more preferably 30 parts by mass or less, and more preferably 20 parts by mass or less, per 100 parts by mass of the synthetic resin. [Example]

[0105] The present invention will be described in more detail below using examples, but the present invention is not limited to these examples.

[0106] The compounds shown below were used as synthetic resins. [Synthetic resin] ·polypropylene

[0107] The compounds shown below were used as inhibitors of viral infection. [Virus infection inhibitor] (organic acid) Terephthalic acid (average particle size: 50 μm) Alginic acid (average particle size: 50 μm) Isophthalic acid (average particle size: 50 μm) (Alkylbenzenesulfonate) Sodium dodecylbenzenesulfonate (average particle size: 50 μm)

[0108] The compounds shown below were used as dispersants. [Dispersant 1 (containing sulfo group salt)] (anionic surfactants) Sodium lauryl sulfonate (average particle size: 50 μm) Sodium polystyrene sulfonate (average particle size: 50 μm, weight-average molecular weight: 200,000)

[0109] [Dispersant 2 (non-sulfo group salt)] (nonionic surfactant) Polyethylene glycol distearate Polyethylene glycol monostearate Polyoxyethylene lauryl ether Lauric acid diethanolamide (Other dispersants) Polyethylene glycol

[0110] (Examples 1 to 19, Comparative Examples 1 to 7) The types of virus infection inhibitors shown in Table 1 were prepared. The types of anionic surfactants shown in Table 1 were prepared as dispersants 1. The types of nonionic surfactants and polyethylene glycol shown in Table 1 were prepared as dispersants 2.

[0111] A masterbatch for synthetic resin molding was prepared by melt-kneading and mixing polypropylene, the type of virus infection inhibitor shown in Table 1, and the types of dispersants 1 and 2 shown in Table 1 at the masterbatch mass ratios (parts by mass) shown in Table 1. The column "Masterbatch mass ratio" in Table 1 shows the amount of each component in the format "mass of polypropylene / mass of virus infection inhibitor / mass of dispersant 1 / mass of dispersant 2." The column "Virus infection inhibitor / dispersant" shows the mass ratio (mass of virus infection inhibitor / total mass of dispersants) of the virus infection inhibitor content to the dispersant content (total content of dispersants 1 and 2).

[0112] The resulting synthetic resin molding masterbatch and separately prepared polypropylene (manufactured by Japan Polypropylene Corporation, trade name "Novatec PP BC6C") were fed to a kneading machine (manufactured by Toyo Seiki Seisaku-sho, trade name "Labo Plastomill 3S150") so that the polypropylene, the virus infection inhibitor of the type shown in Table 1, and Dispersants 1 and 2 shown in Table 1 would be in the mass ratio (parts by mass) of the resin composition (molded product) shown in Table 1. The mixture was melt-kneaded using a roller mixer R60 (manufactured by Toyo Seiki Seisaku-sho) under the kneading conditions shown in Table 2 to prepare a resin composition. The amount of each component is shown in the "mass ratio of resin composition (molded product)" column of Table 1, expressed as "mass of polypropylene / mass of virus infection inhibitor / mass of dispersant 1 / mass of dispersant 2." For kneading conditions 1 to 3, the kneading temperature (°C), kneading speed (rpm), and kneading time (minutes) are shown in Table 2.

[0113] The resulting resin composition was press-molded to obtain a sheet-like virus infection-inhibiting molded article with an average thickness of 1 mm. In the virus infection-inhibiting molded article, the particulate virus infection-inhibiting agent was dispersed in polypropylene.

[0114] The standard deviation σ of the volume fraction of the particulate virus infection inhibitor in the width direction measured by X-ray CT for the obtained virus infection-inhibiting molded body was measured in the manner described above, and the results are shown in the ``Standard deviation σ'' column in Table 1.

[0115] The sphere-equivalent diameter of the particulate virus infection inhibitor obtained in the virus infection-inhibiting molded body was measured by X-ray CT in the manner described above, and the results are shown in the "sphere-equivalent diameter" column in Table 1.

[0116] The antiviral activity of the obtained virus infection-inhibiting molded article was measured in the following manner, and the results are shown in Table 1.

[0117] [Virus infection prevention effect] The obtained virus infection-blocking molded article was subjected to an antiviral test using influenza virus (enveloped virus) in the following manner.

[0118] (Antiviral test) Test pieces were prepared by cutting out a flat square piece measuring 5.0 cm on a side from the virus infection-blocking molded article.

[0119] The surface of the obtained test piece was wiped with a flat square nonwoven fabric (trade name "Kimwipe S-200" manufactured by Nippon Paper Crecia Co., Ltd.) with a side of 10 cm, moving it back and forth 10 times to obtain a test specimen.

[0120] The obtained test specimens were subjected to an antiviral test against influenza virus (test time: 24 hours) in accordance with ISO 21702. The virus suspension was used 10 minutes after the reaction (start of the test) to measure the virus infectivity (common logarithm) of the test specimens (PFU / cm) by the plaque method. 2 ) was calculated.

[0121] A blank reference sample was prepared in the same manner as above, except that no virus infection inhibitor was added. Based on this blank reference sample, the virus infectivity (common logarithm) (PFU / cm) was calculated in the same manner as above. 2 ) was calculated.

[0122] The initial antiviral activity value was calculated by subtracting the viral infectivity of the test sample from the viral infectivity of the blank reference sample.

[0123] [Table 1]

[0124] [Table 2]

Claims

1. A synthetic resin and a particulate virus infection inhibitor contained in the synthetic resin in a dispersed state, the standard deviation σ of the volume fraction of the virus infection inhibitor in the width direction measured by X-ray CT is 0.1 to 5; A virus infection-inhibiting molded article characterized in that the virus infection inhibitor contains at least one compound selected from the group consisting of organic acids, alkylbenzene sulfonates, and amine compounds as an active ingredient.

2. 2. The virus infection-inhibiting molded article according to claim 1, wherein the active ingredient of the virus infection inhibitor contains an organic acid.

3. 3. The virus infection-preventing molded article according to claim 1, further comprising a dispersant.

4. 4. The virus infection-preventing molded article according to claim 3, wherein the dispersant contains a compound containing a salt of a sulfo group in the molecule and / or a compound containing a polyoxyalkylene structure in the molecule.

5. The virus infection-inhibiting molded article according to claim 3, characterized in that the ratio of the content of the virus infection inhibitor to the content of the dispersant (mass of virus infection inhibitor / mass of dispersant) is 0.5 to 20.

6. 3. The virus infection-inhibiting molded article according to claim 1, wherein the virus infection-inhibiting agent has an equivalent sphere diameter of 5 to 30 μm as measured by X-ray CT.

7. 2. The method for producing a virus infection-inhibiting molded article according to claim 1, further comprising the step of melt-kneading a particulate virus infection-inhibiting agent and a synthetic resin.

Images